London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Efficacy and safety of selective laser trabeculoplasty in treatment of primary open-angle glaucoma patients

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Glaucoma II

Session Date/Time: Monday 15/09/2014 | 08:00-10:30

Paper Time: 09:08

Venue: Boulevard F (Level 1)

First Author: : G.Krishtopenko BELARUS

Co Author(s): :    N. Poznyak   S. Poznyak   N. Kovshel        

Abstract Details

Purpose:

The purpose of present work was to study the data of investigations of selective laser trabeculoplasty (SLT) application in treatment of primary open angle glaucoma patients.

Setting:

92 patients – 59 males and 33 females (121 eyes) at the age from 41 to 85 years with primary open angle glaucoma (POAG) were under medical observation.

Methods:

Selective laser trabeculoplasty was performed on Nd: YAG Laser Selecta Duos (Lumenis). First group of patients (50 eyes) underwent 100 laser applications (in all segments of corneascleral trabecula – 360°). In the second group (71 eyes) 50 laser applications (0.8 – 1.2 mJ) in inferior segment were performed (180°).

Results:

Statisticaly significant (p < 0.05) decrease of intraocular pressure (IOP) after SLT was noted in both groups. To the first month this reduction was 3.4 mm Hg in the first group and 1.5 in the second. To the third month – 3.9 and 2.8 respectively. To the sixth month – 3.8 and 2.5 respectively.

Conclusions:

Long effect of SLT was noted in 82% cases in the first group (360°) and 74.6% - in the second (180°). Selective laser trabeculoplasty is safe and effective method of reducing IOP in patients with POAG I-II stages.

Financial Interest:

NONE

Back to previous